Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
5/28/2026, 12:00:00 AM
The US FDA extended the decision date for the SERENA-6 regulatory filing of camizestrant to 2026-05-28 to enable the review of additional data; low market impact (>=1%) expected due to regulatory delay.
Korean Translation
2026년 5월 28일 미국 FDA가 카미제스트란트의 SERENA-6 심사 기한을 연장함. 추가 데이터 검토에 따른 결정 지연으로 1% 이상의 주가 영향이 예상됨.
Related Recent Events
Tempus AI Inc (TEM) · Earnings Release
Tempus AI is scheduled to report its Q2 2026 financial results; earnings releases typically result in price moves of 5% or more, scheduled.
8/14/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
Next earnings release for Q2 2026 on 2026-08-03 is scheduled. Low importance is estimated for the scheduling announcement itself.
8/3/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet's Q2 2026 earnings release is scheduled.
7/28/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Intuitive Surgical's Q2 2026 earnings release, a major stock catalyst, is scheduled.
7/21/2026, 12:00:00 AM
Recursion Pharmaceauticals Inc (RXRX) · Other
2026 Annual Meeting of Stockholders scheduled for June 17, 2026. Market reaction not yet occurred; low importance assigned due to likely <5% price impact from annual meeting scheduled.
6/17/2026, 12:00:00 AM